Skip to main content
. 2015 Feb 6;10(2):e0117215. doi: 10.1371/journal.pone.0117215

Fig 8. Anti-motility and anti-invasive properties of AL776 in 4T1 mouse mammary tumour and MDA-MB-231 triple negative breast cancer cell lines.

Fig 8

(A) 4T1 and (B) MDA-MB-231 cells were treated with 100 nM of AL776 or control drugs gefitinib or dasatinib for a period of 24h and the wound-closure (scratch) was monitored at both 0h and 24h time points. (C) 4T1 or (D) MDA-MB-231 cells were treated with varying doses of AL776 (in comparison with dasatinib or gefitinib) for a period of 24h in a Boyden Chamber invasion assay. Cells were plated in serum-free media (top chamber) and allowed to invade across the layer of matrigel towards media containing 10% FBS (bottom chamber) through chemotaxis. Drugs were added to both the top and bottom chambers to maintain a uniform distribution. Cells were fixed, stained and quantified to generate the percentage of invading cells across the matrigel in comparison with untreated control cells. The histograms represent the average ± SEM of three independent experiments. Statistical analysis was performed using the unpaired two-tailed t-test and p values were obtained (p < 0.05 is significant): 4T1 ** (p = 0.001), MDA-MB-231 * (p < 0.05).